AGIO

Agios Pharmaceuticals · USD

Market closed US (NYSE / Nasdaq) · 09:30–16:00 · Mon 20:53 · approx

Deep AI analysis (big model)

No deep analysis yet. Portfolio holdings are analysed automatically; for any other stock, click “Request deep AI analysis” above.

About Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for genetic blood disorders and cancer through the discovery and development of precision medicines targeting specific genetic mutations.

HealthcareBiotechnologyPharmaceuticals

Ticker	AGIO
Name	Agios Pharmaceuticals
Currency	USD
Sector	Healthcare

Reputation

😎

How liked 50/100

From 0 recent analysed stories — 0 good · 0 bad · 0 neutral. Trend: stable.

Reputation builds as news about this company is analysed.

Price history & forecast

30-day forecast — Linear regression, Holt's exponential smoothing, and drift, plus a news-adjusted consensus (sentiment tilt +0.00). Estimates only, not advice.

Candlestick, volume & news sentiment

…

good bad neutral closed

Open/high/low/close candles with volume beneath; hover for OHLC, change and volume. Dots mark analysed news by sentiment; shaded bands are when the market was closed. Day and Week show intraday detail; Month+ show daily candles. Step through time with ‹ ›.

Forecast accuracy (backtested)

No scored forecasts yet. Every visit records the day's forecast; once those predicted dates pass, this table fills in with how each method actually did (1 snapshot(s) recorded so far, none matured yet).

Technical analysis

BEARISH

43.94

RSI (14)i

28.16

SMA 20i

28.81

SMA 50i

31.72

SMA 200i

0.73%

1di

-2.31%

1wi

-2.59%

1mi

2.46%

30d voli

45.49

52w highi

22.34

52w lowi

-39.68%

from highi

-0.29

MACDi

Downtrend (50d below 200d)MACD bearish crossover

Computed from 258 locally-stored price bars.

AI signals

HOLD 35% · swing 2026-06-08 10:30

AGIO is consolidating after a volatile window with no visible catalysts. The stock recovered from a June 2 low of $26.51 to $28.79, indicating bid support in the mid-$20s, but the +1.1% net change and absence of headlines suggest indecision. Biotech valuations are highly event-driven; without near-term clinical, regulatory, or partnership updates, price action is likely to remain range-bound until a catalyst emerges. A HOLD stance preserves capital while monitoring for breakout/breakdown levels around $30.40 (resistance) and $26.50 (support). This analysis is informational and does not constitute financial advice; biotech positions carry elevated binary risk and should be sized accordingly.

qwen3.6:latest